A novel bioassay for quantification of surface Cannabinoid receptor 1 expression

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• The cannabinoid receptor type 1 (CB1) is crucial for physiological processes, and its gene (CNR1) mutations are linked to diseases.
• Current methods for quantifying CB1 expression and localization have significant disadvantages and potential for errors.
• CB1 receptor dysfunction is implicated in various neurological and metabolic disorders, making it a key pharmacological target.

Purpose of the Study:

• To develop and validate a sensitive bioassay for quantifying cell surface CB1 receptor expression.
• To assess the correlation between the bioassay signal and CB1 receptor localization.
• To demonstrate the assay's reliability by comparing it with existing methods and known CNR1 mutations.

Main Methods:

• A novel bioassay was developed by fusing Gaussia Luciferase (GLuc) to the extracellular domain of the CB1 receptor.
• GLuc activity was measured by adding coelenterazine to the cell medium and performing immediate readouts.
• Assay validation involved comparing results with previously reported CNR1 mutations and flow cytometry analysis.

Main Results:

• The GLuc activity assay demonstrated a strong correlation with CB1 receptor localization on the cell surface.
• The bioassay successfully identified and quantified the effects of known CNR1 gene mutations.
• Results obtained from the GLuc-based assay were consistent with those from flow cytometry.

Conclusions:

• The developed GLuc-based bioassay provides a sensitive and reliable method for quantifying cell surface CB1 receptor expression.
• This assay can effectively screen receptor levels and elucidate the impact of clinically relevant mutations or polymorphisms on CB1.
• The methodology holds potential for application in detecting membrane-bound levels of other G protein-coupled receptors (GPCRs).